Clinical Trial Detail

NCT ID NCT02873819
Title Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Gliknik Inc.
Indications

oral squamous cell carcinoma

Therapies

MAGE-A3 vaccine

Cyclophosphamide + Poly ICLC + Sargramostim

Age Groups: adult senior

No variant requirements are available.